$KRBP News

Last published 1y ago

1y agoKRBPKiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free SurvivalBusiness WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial
1y agoKRBPKiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01Business WireProvides Enrollment Update for Phase 1 Study in Late-Stage Non-small Cell Lung Cancer Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable efficacy results from the 12-month follow-up
1y agoKRBPKiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01Business WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from the eight-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical
1y agoKRBPKiromic BioPharma Announces Settlement of Previously Disclosed SEC InvestigationBusiness WireSEC declines to impose civil penalties in light of the Company's self-reporting, prompt remediation and cooperation Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") today announced that it has entered
2y agoKRBPKiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01Business WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its Deltacel-01 Phase 1 clinical trial. This trial is
2y agoKRBPKiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical TrialBusiness WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports good safety and favorable ongoing efficacy results from the 10-month follow-up visit of the first patient treated in its Deltacel-01 Phase 1
2y agoKRBPKiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialBusiness WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in the Deltacel-01 Phase 1 trial
2y agoKRBPKiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous RecommendationBusiness WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announced today that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion phase of the
2y agoKRBPKiromic BioPharma's Deltacel Receives FDA Fast Track DesignationBusiness WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Deltacel™ (KB-GDT-01), the Company's allogeneic,
2y agoKRBPKiromic BioPharma Provides Update on Part 1 of the Deltacel-01 TrialBusiness WireOn track to initiate Part 2 in September Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is
2y agoKRBPKiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01Business WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company"), reports favorable eight-month follow-up results from the first patient enrolled in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating
2y agoKRBPKiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion PhaseBusiness WireEnrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial's Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc.
2y agoKRBPKiromic BioPharma Provides Updates on its Deltacel-01 Clinical TrialBusiness WireFollow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial's Second Cohort
2y agoKRBPKiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical TrialBusiness WireFavorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable six-month follow-up results from the first
2y agoKRBPKiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial SiteBusiness WireKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating
2y agoKRBPKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsBusiness WireFollow-up Scans Show Continued Stable Disease in First Patient Cohort Company to Apply for FDA Fast Track Designation Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces consistent favorable
2y agoKRBPKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialBusiness WireTrial's Safety Monitoring Committee Recommends Maintaining Initial Cell Dose Level for Next Cohort of Patients Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports early efficacy results showing
2y agoKRBPEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical TrialBusiness WireFavorable Safety and Tolerability also Observed Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports early efficacy results showing primary lung tumor stabilization and the complete disappearance
2y agoKRBPKiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialBusiness WireThird Patient Enrolled in Deltacel-01 Completes Treatment Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the
2y agoKRBPKiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7thBusiness WireLive and Archived Fireside Chat Available at VirtualInvestorConferences.com Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that Chief Executive Officer Pietro Bersani, Chief Financial
2y agoKRBPKiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7thGlobeNewswireHOUSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief
2y agoKRBPResults from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsBusiness WireSecond Patient Completed Treatment and Third Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company")
2y agoKRBPKiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung CancerBusiness WireStabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable early efficacy results from the first patient
2y agoKRBPKiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical TrialBusiness WireCompany Executives Available to Meet with Investment Professionals January 8-10 in San Francisco Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company"), a clinical-stage, fully-integrated biotherapeutics
2y agoKRBPKiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung CancerBusiness WireInitial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company"), a
3y agoKRBPKiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14Business WireKRBP Suspended from Trading on Nasdaq Kiromic BioPharma (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial
3y agoKRBPKiromic BioPharma Welcomes Two New Directors to its BoardBusiness WireClinical and Regulatory Affairs Expert Pamela Misajon Brings Drug-Development Expertise Finance and Technology Executive Michael Catlin to Chair the Audit Committee Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic"
3y agoKRBPKiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung CancerBusiness WireCompany Expects Beginning of First in Human Trial Activation in Second Quarter of 2023 Deltacel is Being Developed to Treat Solid Malignancies, Which Comprise 90% of All Cancers Kiromic BioPharma, Inc. (NASDAQ:KRBP)
3y agoKRBPKiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung CancerBusiness WireDeltacel is Being Developed as an Allogeneic, Non-Viral, Non-Engineered Off-the-Shelf Gamma Delta T-Cell Therapy Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated
3y agoKRBPKiromic BioPharma Announces Reverse Stock SplitBusiness WireKiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to
3y agoKRBPKiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology ResultsBusiness WireFavorable Safety Results are Last Component Needed to Complete the Nonclinical Module of the Company's IND Application IND Submission and Activation of Clinical Trial Process on Track for the First Quarter and Second
3y agoKRBPTwo Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote "FOR" All Proxy ProposalsBusiness WireISS and Glass Lewis Join the Kiromic Board of Directors in Recommending Stockholders Vote "FOR" for All Three Proposals at the Special Meeting of Kiromic Stockholders to be Held on March 7, 2023 Kiromic BioPharma, Inc.
3y agoKRBPKiromic BioPharma CEO Issues Letter to StockholdersBusiness WireKiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to
4y agoKRBPKiromic BioPharma Arranges Up to $10 Million FinancingBusiness WireLitigation with Sabby and Another Institutional Shareholder Settled Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the October
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 29, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octob
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 27, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octob
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 22, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octob
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 21, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octob
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 19, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octo
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 15, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octob
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 13, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octo
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 8, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octobe
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 7, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octobe
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 5, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octobe
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the Octobe
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 30, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the October
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 25, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the October
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 24, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the October
4y agoKRBPSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 22, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the October